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Abstract
Introduction Antenatal maternal administration of corti-
costeroids has been shown to reduce morbidity and mor-
tality rates in preterm delivery. Threatened spontaneous or
medically indicated preterm delivery for maternal or fetal
indications between 24 and 34 weeks of gestation with
unknown fetal lung maturity status are indications for
antenatal corticosteroid administration. Recent studies have
challenged current practice of antenatal glucocorticoid use.
The goal of this expert letter is to provide recommenda-
tions based for the clinical use of antenatal glucocorticoids
based on the current evidence from published studies.
Methods The published literature (PubMed search), as
well as the recommendations of other national societies,
has been searched and taken into consideration for these
recommendations.
Results/conclusions The standard regimen of antenatal
corticosteroids involves a single course of 2 9 12 mg
betamethasone administered intramuscularly within 24 h.
The administration of corticosteroids usually is performed
between 24 and 34 weeks gestation. However, under par-
ticular circumstances it may be beneficial even at 23 weeks
and at 35–36 weeks of gestation. The evidence to date is
clearly against the routine administration of multiple
antenatal steroid courses. In special clinical situations, a
second course of betamethasone (‘‘rescue course’’) may be
justifiable. Tocolysis during administration of steroids is
not routinely indicated in the absence of contractions,
cervical shortening or rupture of membranes.
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Introduction
It has been known for years that antenatal maternal
administration of corticosteroids reduces morbidity and
mortality rates in cases of preterm delivery. Large ran-
domized studies have shown a 50 % reduction in the
incidence of respiratory distress syndrome (RDS) follow-
ing administration of antenatal corticosteroids, as well as
other complications such as severe intraventricular hem-
orrhage and necrotizing enterocolitis [1, 2]. This treatment
can reduce the overall mortality of preterm delivery by
approximately 50 %. Furthermore, the administration of
antenatal steroids does not increase the risk of sepsis in
premature infants.
Until recently, the dosing regimen of corticosteroids for
fetal lung maturation was debated. Although several
smaller studies suggested that repeated courses of corti-
costeroids could have certain benefits, others, including
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some animal studies, showed possible impairment of fetal
neurodevelopment. Contradictory findings in the literature
also exist regarding the timing of administration and the
type of corticosteroid which should be given. Thus, the
goal of this expert letter is to create a unified consensus
with evidence-based recommendations regarding the
administration of antenatal corticosteroids. The available
literature, as well as the recommendations of other national
societies, has been taken into consideration for these
recommendations.
Indications for administration of antenatal
corticosteroids
Threatened spontaneous delivery or medically indicated
preterm delivery for maternal or fetal (e.g., severe intra-
uterine growth restriction due to placental insufficiency or
preeclampsia) indications between 24 and 34 weeks of
gestation with unknown fetal lung maturity status as well
as documented pulmonary immaturity after 34 weeks of
gestation (surfactant/albumin ratio \55).
Recently published, non-randomized studies have sug-
gested that the administration of corticosteroids at
23 weeks of gestation may be beneficial and help reduce
neonatal mortality, even at this extremely premature age
[3]. Therefore, antenatal steroids may be administered
several days prior to 24 weeks of gestation, depending on
the individual case and indication.
After 34 weeks of gestation, severe long-term neonatal
morbidity is not significantly higher as in those delivered at
term. Nevertheless, the risks of pulmonary complications
(RDS, possibly pneumothorax) and neonatal infection are
the main concerns in neonates delivered at this gestational
age, although the risk of RDS continuously decreases from
this point until term. No larger studies regarding antenatal
corticosteroid administration in preterm delivery after
34 weeks of gestation exist, which demonstrate its efficacy
in this time period [4]. Nevertheless, one randomized study
of nearly 1,000 pregnant women prior to elective cesarean
section in the 37th to 39th week of pregnancy demonstrated
a significant (50 %) reduction of pulmonary complications
up to the 38th week of gestation when corticosteroids had
been administered [5]. This study also showed that delay-
ing the timing of elective cesarean section until 39 weeks
of gestation had the equivalent or an even better effect than
antenatal steroids. Thus, a carefully timed cesarean section
(after 39 0/7 weeks gestation) is preferable to steroids,
which may have possible fetal side effects. On the other
hand, it can be assumed from these data that antenatal
corticosteroids have an effect on pulmonary maturity even
after 34 weeks of gestation, which would be biologically
plausible. Therefore, in the case of preterm delivery at
35–36 weeks of gestation and in the absence of extreme
time pressure to deliver the fetus, the administration of
antenatal steroids could be considered prior to cesarean
section as well as prior to induction of labor. This coincides
with the guidelines of the Royal College of Obstetricians
and Gynaecologists (RCOG) [6]. Nevertheless, the risks
and benefits of antenatal corticosteroid administration and
the individual clinical situation must be carefully consid-
ered. In general, it appears that the potential risks of
antenatal steroids as well as those of prolonging pregnancy,
for example, in the case of premature rupture of mem-
branes, outweigh the likely limited benefits of steroid
administration after this time point.
Contraindications against antenatal glucocorticoid
administration
Antenatal glucocorticoid administration is contraindicated
when urgent delivery of the fetus is needed (e.g., patho-
logical fetal heart rate tracing, placental abruption) [7].
Severe, fulminant chorioamnionitis is another contrain-
dication; immediate delivery is indicated in these cases. In
contrast, mild, generalized signs of maternal infection,
in particular in very early gestational ages (less than
26 weeks) do not comprise an absolute contraindication to
administration of antenatal glucocorticoids [8, 9]. In this
situation, therapy with a broad-spectrum antibiotic is
essential, and the risks and benefits of antenatal steroids
versus immediate delivery must be carefully weighed.
Non-gynecological infections as well as well-controlled
maternal diabetes mellitus (gestational diabetes or preex-
isting type 1 or 2 diabetes) are not contraindications against
antenatal corticosteroid administration. In the case of dia-
betes mellitus, blood glucose values must be closely
monitored during therapy and insulin dosages adjusted
accordingly [2].
In cases of preeclampsia between 24 and 34 weeks of
gestation, antenatal steroids can be administered as long as
delivery can be safely delayed for at least 12–24 h [10].
Additionally, steroids may help stabilize platelet and liver
enzyme levels in the case of thrombocytopenia and ele-
vated liver enzymes in HELLP syndrome, thus justifying
the administration of betamethasone even shortly before or
after delivery. Whether the effects are simply ‘‘cosmetic’’
or have a truly beneficial effect on the progress of HELLP
syndrome, however, remains unclear.
Administration of antenatal corticosteroids
The standard regimen of antenatal corticosteroids involves
12 mg betamethasone administered intramuscularly,
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repeated once after 24 h (2 9 2 ampules of Celestone
Chronodose; 1 ampule = 3 mg betamethasone natrium
phosphate plus 3 mg betamethasone acetate).
In the very rare instance when intramuscular adminis-
tration is contraindicated (e.g., extremely elevated risk of
bleeding), Celestan i.v. (2 9 3 ampules of 1 ml, each
containing 4 mg betamethasone, dosage repeated once
after 24 h) may be given. However, the intravenous regi-
men has not been evaluated in studies; in particular, there is
no evidence for a more rapid effect with the i.v. adminis-
tration, even when the interval between doses is shortened
to 12 or 6 h. Therefore, the intramuscular administration of
corticosteroids as described above comprises the interna-
tional, evidence-based standard. Oral administration is
obsolete [11]. Recent evidence suggests that a 12-h interval
might be equivalent to the standard 24-h interval. However,
the incidence of necrotizing enterocolitis is increased and
therefore the 12-h interval cannot be recommended [12].
The full effect of antenatal corticosteroids is reached
48 h after first administration of the medication [13].
Repeated courses of antenatal corticosteroids?
In many European clinics in the 1990s, repeated courses of
antenatal corticosteroids were often administered in 1- to
2-week intervals, since their effectiveness on pulmonary
maturity was well known. At that time, there was no evi-
dence from randomized studies demonstrating any addi-
tional benefit to repeating steroid courses. It was, however,
becoming increasingly apparent that glucocorticoids could
have potential negative effects in the fetus, particularly on
the central nervous system. They affect primarily the pro-
liferation and differentiation of oligodendrocytes, which
are responsible for generation of the myelin sheath around
the pyramidal tract. This is especially important in the third
trimester of pregnancy, when cellular division of oligo-
dendrocytes reaches its peak. Animal studies have shown
neurological developmental deficits in newborns following
multiple courses of antenatal steroids in comparison with a
single course [14, 15].
In addition, repeated administration of steroids resulted
in lower birth weights, decreased brain size at birth and
reduced neuronal myelinization [16–20].
Since then, the results from several large randomized
clinical studies have been published [17, 21–24]. With the
exception of one group [21], none of the studies showed
any significant benefit for the newborn. Furthermore, the
largest study, which included nearly 2,000 patients [17],
confirmed the negative effects of repeated courses of
antenatal steroids, including diminished birth weight, body
length and head circumference at birth in comparison with
administration of a single course. One study [24] was even
terminated early due to the increased (although not statis-
tically significant) incidence of cerebral palsy in the group
receiving repeated courses of corticosteroids.
The conclusion that can be made from these studies is
that the findings to date are against the routine adminis-
tration of multiple antenatal steroid courses. Long-term
outcomes of the children in these studies are not yet
available.
It was assumed in certain clinical situations, namely, in
acute deterioration with renewed threatened preterm
delivery, that repeating antenatal steroids once (‘‘rescue
course’’) could be advantageous. Although there has been
limited evidence to date to support this, a recently pub-
lished, randomized study with nearly 500 patients showed
that a second course of antenatal steroids administered up
to 32 weeks of gestation—with a minimal interval of
2 weeks from the first course—can improve neonatal out-
come without increasing short-term risks [25]. In specific
clinical situations (e.g., first course of steroids administered
very early in the pregnancy, e.g., 24 weeks of gestation,
followed by deterioration of the situation 4–6 weeks later),
the authors believe that a single repeated course of steroids
(‘‘rescue course’’) can be justified.
Short- and long-term effects of antenatal
glucocorticoids on fetus and newborn
Antenatal administration of glucocorticoids has several
well-known short-term effects on the fetus [26]. Fetal heart
rate as determined by cardiotocography shows marked
reduction of variability, 2–3 days after betamethasone
administration. These changes are thought to due to a shift
in the sympatho-vagal balance [27]. Similarly, fetal body
movements and breathing activity are reduced. Fetal
magnetoencephalographic studies suggest that administra-
tion of betamethasone to expectant mothers was associated
with acute change in higher cortical functions in the
exposed fetuses [28]. Doppler flow measurements in the
umbilical artery are unchanged in fetuses with normal
pulsatility before administration. However, in fetuses with
absent or reversed end-diastolic flow in the umbilical artery
show decreasing vascular resistance in the placental cir-
culation, leading to return of end-diastolic flow and
decreased pulsatility in the umbilical artery. These changes
can be observed in two-third of all cases 24 h after beta-
methasone injection and last for a median of 72 h (in single
cases up to 10 days). If this phenomenon is beneficial or
harmful for the fetus, is a matter of debate.
Less is known about long-term effects of antenatal
glucocorticoids on neonatal and child development. In
newborns exposed to a single course of antenatal beta-
methasone, cardiac autonomic balance seems to be
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preserved in neonates [29]. In children, some effects on
behavior were described in some studies [30], while studies
in adults showed no alterations of cognitive functioning,
working memory and attention, psychiatric morbidity,
handedness, or health related quality of life after a single
course of antenatal betamethasone [31]. Fetal programming
effects on cardiovascular functions (e.g., hypertension)
have been described in humans and are currently further
studied in animal models [32].
Practical issues
Antenatal corticosteroids are best administered in an in-
patient setting. Tocolysis during administration of steroids
is not routinely indicated in the absence of contractions,
cervical shortening or rupture of membranes. A note of
caution: concurrent administration of antenatal corticoste-
roids and tocolysis using beta-mimetics in the presence of
maternal infection increases the risk of development of
pulmonary edema [33, 34].
Careful counseling of the couple prior to administration
of antenatal corticosteroids, particularly between 23 and
25 weeks of gestation and preferentially in the presence of
a neonatologist, is essential. Furthermore, the course of
action regarding fetal monitoring and potential intervention
(cesarean section) for fetal indications during this time
period should be clearly established with the couple and
carefully documented. Likewise, the care of the neonate in
case of delivery (maximal intervention with full resusci-
tation efforts vs. comfort care) must be discussed with the
neonatologist in advance. Ideally, the plan should be
established in an interdisciplinary setting whenever possi-
ble. Regarding this topic, one can refer to the interdisci-
plinary guidelines from the Swiss Society of Neonatology
from 2011 on the care of the premature infant at the edge of
viability [35].
Another important measure involves expedient transfer
of the pregnant woman from 22 weeks onwards to a peri-
natal center with a neonatal intensive care unit capable of
treating neonates delivered prior to 34 weeks of gestation.
Many studies have shown that neonatal morbidity and
mortality can be reduced through this action. The first dose
of corticosteroids should be administered prior to transfer
of the patient.
Although administering antenatal betamethasone for
fetal lung maturity must be regarded as off-label use, the
authors and the quality assurance commission of the Swiss
Society of Gynecology and Obstetrics believes that official
informed consent is not necessary in this case, since its use
is undisputed and no other alternative, licenced drugs exist
to date.
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